Literature DB >> 35862749

Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients.

Brian P Epling1, John H Powers2.   

Abstract

Entities:  

Keywords:  Acinetobacter; antimicrobial agents; comparative studies; multidrug resistance

Mesh：

Substances：

Year:  2022        PMID： 35862749      PMCID： PMC9380567          DOI： 10.1128/aac.00766-22

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.938


× No keyword cloud information.
  8 in total

1.  Making inferences on treatment effects from real world data: propensity scores, confounding by indication, and other perils for the unwary in observational research.

Authors:  Nick Freemantle; Louise Marston; Kate Walters; John Wood; Matthew R Reynolds; Irene Petersen
Journal:  BMJ       Date:  2013-11-11

2.  Scientific Evidence, Regulatory Decision Making, and Incentives for Therapeutics in Infectious Diseases: The Example of Cefiderocol.

Authors:  John H Powers
Journal:  Clin Infect Dis       Date:  2021-06-15       Impact factor: 9.079

3.  Excess deaths associated with tigecycline after approval based on noninferiority trials.

Authors:  Paritosh Prasad; Junfeng Sun; Robert L Danner; Charles Natanson
Journal:  Clin Infect Dis       Date:  2012-03-30       Impact factor: 9.079

4.  Cefiderocol- Compared to Colistin-Based Regimens for the Treatment of Severe Infections Caused by Carbapenem-Resistant Acinetobacter baumannii.

Authors:  Marco Falcone; Giusy Tiseo; Alessandro Leonildi; Leonardo Della Sala; Alessandra Vecchione; Simona Barnini; Alessio Farcomeni; Francesco Menichetti
Journal:  Antimicrob Agents Chemother       Date:  2022-03-21       Impact factor: 5.938

5.  A most stubborn bias: no adjustment method fully resolves confounding by indication in observational studies.

Authors:  Jaclyn L F Bosco; Rebecca A Silliman; Soe Soe Thwin; Ann M Geiger; Diana S M Buist; Marianne N Prout; Marianne Ulcickas Yood; Reina Haque; Feifei Wei; Timothy L Lash
Journal:  J Clin Epidemiol       Date:  2009-05-19       Impact factor: 6.437

6.  The importance of colonization pressure in multiresistant Acinetobacter baumannii acquisition in a Greek intensive care unit.

Authors:  Kostoula Arvaniti; Dimitrios Lathyris; Raymond Ruimy; Anna-Bettina Haidich; Vasiliki Koulourida; Pavlos Nikolaidis; Dimitrios Matamis; Spiros Miyakis
Journal:  Crit Care       Date:  2012-06-13       Impact factor: 9.097

7.  An Introduction to Propensity Score Methods for Reducing the Effects of Confounding in Observational Studies.

Authors:  Peter C Austin
Journal:  Multivariate Behav Res       Date:  2011-06-08       Impact factor: 5.923

8.  Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial.

Authors:  Matteo Bassetti; Roger Echols; Yuko Matsunaga; Mari Ariyasu; Yohei Doi; Ricard Ferrer; Thomas P Lodise; Thierry Naas; Yoshihito Niki; David L Paterson; Simon Portsmouth; Julian Torre-Cisneros; Kiichiro Toyoizumi; Richard G Wunderink; Tsutae D Nagata
Journal:  Lancet Infect Dis       Date:  2020-10-12       Impact factor: 71.421
  8 in total
  1 in total

1.  Reply to Epling and Powers, "Cefiderocol and the Need for Higher-Quality Evidence: Methods Matter for Patients".

Authors:  Marco Falcone; Giusy Tiseo
Journal:  Antimicrob Agents Chemother       Date:  2022-07-18       Impact factor: 5.938
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.